About UAMSCollegesInstitutesHospital and Clinics GivingEmploymentEducationPatients and VisitorsResearch
Home » Faculty » William E. Fantegrossi
William E. Fantegrossi

Assistant Professor


University of Michigan, 2002

Research Interests
Research conducted in my lab focuses on the in vivo pharmacology of drugs of abuse. One major interest concerns "emerging" street drugs, including designer cannabinoids and hallucinogens, especially as pertains to abuse liability assessment and, in partnership with medicinal chemists, development of structure-activity relationships. A second focus of investigation seeks to assess the efficacy of novel compounds generated by natural products chemists as potential pharmacotherapeutics against psychostimulant abuse. More recently, we have become interested in relating experience with early life visceral pain to subsequent sensitivity to opioid abuse, and determining how pain-elicited alterations in opioid receptor expression and function may mediate these effects. Rodent models of intravenous drug self-administration, drug discrimination, food-maintained behavior, delayed matching to position, locomotor activity, and assays of drug-elicited behavior are employed in order to better understand the neuropharmacology of these drugs of abuse, as well as to probe biological mechanisms of drug dependence. Similarly, in collaboration with colleagues at UAMS and at other institutions, we are using PET neuroimaging and magnetic resonance spectroscopy to study the persistent effects of abused drugs on neurochemistry and behavior. Finally, we participate in multi-site pre-clinical evaluations of the abuse liability of novel pharmacological entities submitted by federal, academic, and industrial sources. 



Research page and video
Fantegrossi Research

Selected Publications

Brents LK, Gallus-Zawada A, Radominska-Pandya A, Vasiljevik T, Prisinzano TE, Fantegrossi WE, Moran JH, Prather PL. Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity. Biochem Pharmacol, 83(7):952-61, 2012.

Murnane KS, Perrine SA, Finton BJ, Galloway MP, Howell LL, Fantegrossi WE. Effects of exposure to amphetamine derivatives on passive avoidance performance and the central levels of monoamines and their metabolites in mice: correlations between behavior and neurochemistry. Psychopharmacology (Berl), 220(3):495-508, 2012.

Brents LK, Reichard EE, Zimmerman SM, Moran JH, Fantegrossi WE, Prather PL. Phase I hydroxylated metabolites of the K2 synthetic cannabinoid JWH-018 retain in vitro and in vivo cannabinoid 1 receptor affinity and activity. PLoS One, 6(7):e21917, 2011.

Moran CL, Le VH, Chimalakonda KC, Smedley AL, Lackey FD, Owen SN, Kennedy PD,  Endres GW, Ciske FL, Kramer JB, Kornilov AM, Bratton LD, Dobrowolski PJ, Wessinger WD, Fantegrossi WE, Prather PL, James LP, Radominska-Pandya A, Moran JH. Quantitative measurement of JWH-018 and JWH-073 metabolites excreted in human urine. Anal Chem, 83(11):4228-36, 2011.

Matsumoto RR, Li SM, Katz JL, Fantegrossi WE, Coop A. Effects of the selective sigma receptor ligand, 1-(2-phenethyl)piperidine oxalate (AC927), on the behavioral and toxic effects of cocaine. Drug Alcohol Depend, 118(1):40-7, 2011.

Howell LL, Fantegrossi WE. Intravenous Drug Self-Administration in Nonhuman Primates. In: Buccafusco JJ, editor. Methods of Behavior Analysis in Neuroscience. 2nd edition. Boca Raton (FL): CRC Press; Chapter 9, 2009.

Fantegrossi WE, Simoneau J, Cohen MS, Zimmerman SM, Henson CM, Rice KC, Woods  JH. Interaction of 5-HT2A and 5-HT2C receptors in R(-)-2,5-dimethoxy-4-iodoamphetamine-elicited head twitch behavior in mice. J Pharmacol Exp Ther, 335(3):728-34, 2010.

Murnane KS, Fantegrossi WE, Godfrey JR, Banks ML, Howell LL. Endocrine and neurochemical effects of 3,4-methylenedioxymethamphetamine and its stereoisomers in rhesus monkeys. J Pharmacol Exp Ther, 334(2):642-50, 2010.

View Dr. Fantegrossi's PubMed publication list.